Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study Print E-mail
Tuesday, 30 June 2015 09:55
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical Company focused on the development of oral drug delivery systems, announced today that the first patient has been screened in the Company's Phase IIb trial of its oral insulin capsule, ORMD-0801.  
Read more...
 
AAA Signs Distribution Agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD Print E-mail
Tuesday, 30 June 2015 09:19
Advanced Accelerator Applications S.A. (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), announces that it has entered into a distribution agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD (“FRI”), a leading in-country distributor of nuclear medicine and diagnostic imaging products. Lutathera is currently in a pivotal Phase III trial, both in the US and EU, with results expected in Q3.
Read more...
 
PharmaCyte Biotech Enters into Research and Consulting Agreements with University of Technology Sydney Print E-mail
Tuesday, 23 June 2015 10:35
SILVER SPRING, MD--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has signed a major Research Services Agreement and an important Consulting Contract with the University of Technology Sydney (UTS) in Australia.
Read more...
 
PlasmaTech Biopharmaceuticals Announces Name Change to Abeo Print E-mail
Friday, 19 June 2015 08:53
NEW YORK, NY--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and
plasma-based products for severe and

Error. Page cannot be displayed. Please contact your service provider for more details. (15)

life-threatening rare diseases, today announced a name change to Abeona Therapeutics, Inc. to reflect its broader rare disease commitment.
Read more...
 
PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders Print E-mail
Monday, 15 June 2015 08:10
NEW YORK, NY and CLEVELAND, OH--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that it has added another adeno-associated virus (AAV) gene therapy program to its product pipeline. The Company has licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases.
Read more...
 
PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders Print E-mail
Monday, 15 June 2015 08:10
NEW YORK, NY and CLEVELAND, OH--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that it has added another adeno-associated virus (AAV) gene therapy program to its product pipeline. The Company has licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases.
Read more...
 
PlasmaTech Biopharmaceuticals Announces License Agreement for AAV Gene Therapy to Treat Patients With Juvenile Batten Disease Print E-mail
Monday, 08 June 2015 09:13
 New York, NY (June 8, 2015) PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases announced today that it has added another adeno-associated virus (AAV) gene therapy program to its product pipeline.
Read more...
 
Actinium's Clinical Data Generate Significant Interest at 2015 ASCO Annual Meeting Print E-mail
Thursday, 04 June 2015 12:39
NEW YORK, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the presentation of poster and abstract at ASCO 2015, the 51stAnnual Meeting of American Society of Clinical Oncology, was given in Chicago on May 31.
Read more...
 
Pluristem Awarded Grant from Israel’s Ministry of Economy for Marketing its PLX Cell Therapy in Japan Print E-mail
Wednesday, 03 June 2015 19:22
HAIFA, ISRAEL--Pluristem Therapeutics Inc. (NasdaqCM: PSTI), a leading developer of placenta-based cell therapy products, today announced that it has been awarded a Smart Money grant from Israel’s Ministry of Economy.
Read more...
 
Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel Print E-mail
Monday, 01 June 2015 14:36
Haifa, Israel, June 1, 2015 -- Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, today announced it has been granted patents covering cell manufacturing, pharmaceutical compositions and disease treatment in China, South Korea, Mexico, Russia, and Israel.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 2 of 12
BMR:1